Kantarjian H - Search Results

1

The topoisomerase I inhibitor DX-8951f is active in a severe combined immunodeficient mouse model of human acute myelogenous leukemia.

Vey N, Giles FJ, Kantarjian H, Smith TL, Beran M, Jeha S. Vey N, et al. Among authors: kantarjian h. Clin Cancer Res. 2000 Feb;6(2):731-6. Clin Cancer Res. 2000. PMID: 10690560

2

Bone marrow hypoplasia and aplasia complicating interferon therapy for chronic myelogenous leukemia.

Talpaz M, Kantarjian H, Kurzrock R, Gutterman JU. Talpaz M, et al. Among authors: kantarjian h. Cancer. 1992 Jan 15;69(2):410-2. doi: 10.1002/1097-0142(19920115)69:2<410::aid-cncr2820690222>3.0.co;2-v. Cancer. 1992. PMID: 1370212

3

Molecular approaches to purging of chronic myelogenous leukemia marrow in autologous transplantation.

Yuan T, Zhou YQ, Herst CV, Reading C, Ellersen D, Etkin M, Khouri I, Kantarjian H, Talpaz M, Deisseroth A. Yuan T, et al. Among authors: kantarjian h. Prog Clin Biol Res. 1992;377:227-30. Prog Clin Biol Res. 1992. PMID: 1438419 No abstract available.

4

Treatment of newly diagnosed acute myelogenous leukemia with granulocyte-macrophage colony-stimulating factor (GM-CSF) before and during continuous-infusion high-dose ara-C + daunorubicin: comparison to patients treated without GM-CSF.

Estey E, Thall PF, Kantarjian H, O'Brien S, Koller CA, Beran M, Gutterman J, Deisseroth A, Keating M. Estey E, et al. Among authors: kantarjian h. Blood. 1992 May 1;79(9):2246-55. Blood. 1992. PMID: 1571541 Free article.

5

Evolution of treatment for acute myelogenous leukemia and myelodysplastic syndrome at M.D. Anderson Cancer Center 1985-1991.

Keating MJ, Estey E, Kantarjian H, Plunkett W, O'Brien S, Koller C, Beran M, Freireich EJ. Keating MJ, et al. Among authors: kantarjian h. Leukemia. 1992;6 Suppl 2:78-80. Leukemia. 1992. PMID: 1578950 Review. No abstract available.

6

AML-associated cytogenetic abnormalities (inv (16), del (16), t(8;21)) in patients with myelodysplastic syndromes.

Estey E, Trujillo JM, Cork A, O'Brien S, Beran M, Kantarjian H, Keating M, Freireich EJ, Stass S. Estey E, et al. Among authors: kantarjian h. Hematol Pathol. 1992;6(1):43-8. Hematol Pathol. 1992. PMID: 1601822

7

CI-973, a new platinum derivative with potential antileukemic activity.

O'Brien S, Kantarjian H, Freireich E, Johnston D, Nguyen K, Beran M. O'Brien S, et al. Among authors: kantarjian h. Cancer Res. 1992 Aug 1;52(15):4130-4. Cancer Res. 1992. PMID: 1638526

8

Fludarabine: a new agent with marked cytoreductive activity in untreated chronic lymphocytic leukemia.

Keating MJ, Kantarjian H, O'Brien S, Koller C, Talpaz M, Schachner J, Childs CC, Freireich EJ, McCredie KB. Keating MJ, et al. Among authors: kantarjian h. J Clin Oncol. 1991 Jan;9(1):44-9. doi: 10.1200/JCO.1991.9.1.44. J Clin Oncol. 1991. PMID: 1702145 Clinical Trial.

9

Interferon-stimulated genes in interferon-sensitive and -resistant chronic myelogenous leukemia patients.

Talpaz M, Chernajovsky Y, Troutman-Worden K, Wetzler M, Kantarjian H, Gutterman JU, Kurzrock R. Talpaz M, et al. Among authors: kantarjian h. Cancer Res. 1992 Mar 1;52(5):1087-90. Cancer Res. 1992. PMID: 1737366

10

Gemcitabine in leukemia: a phase I clinical, plasma, and cellular pharmacology study.

Grunewald R, Kantarjian H, Du M, Faucher K, Tarassoff P, Plunkett W. Grunewald R, et al. Among authors: kantarjian h. J Clin Oncol. 1992 Mar;10(3):406-13. doi: 10.1200/JCO.1992.10.3.406. J Clin Oncol. 1992. PMID: 1740680 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

2,533 results

Search Page

Filters